Optimal management of T2DM remains elusive

被引：0
|
作者：
Rury R. Holman
机构：
[1] Diabetes Trials Unit,
[2] The Oxford Centre for Diabetes,undefined
[3] Endocrinology and Metabolism,undefined
[4] University of Oxford,undefined
[5] Churchill Hospital,undefined
来源：
Nature Reviews Endocrinology | 2013年 / 9卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Worldwide, >366 million people with type 2 diabetes mellitus remain at excess risk of cardiovascular disease and face a lifetime of treatment escalation for this progressive disorder. Studies in 2012 have re-affirmed the safety of early insulin treatment, metformin use in renal impairment, and shown β-cell function preservation over several years.
引用
收藏
页码：67 / 68
页数：1
相关论文
共 50 条
  • [21] Preptin as a Potential Marker in Iraqi Newly Diagnosed T2DM and T2DM with Cardiovascular Disease
    Tahir, Noor Thair
    Al-Khateeb, Shatha M. J.
    Akram, Raghda Shams
    [J]. JOURNAL OF CONTEMPORARY MEDICAL SCIENCES, 2024, 10 (02): : 102 - 105
  • [22] T2DM/CKD genetic risk scores and the progression of diabetic kidney disease in T2DM subjects
    Galuska, David
    Pacal, Lukas
    Chalasova, Katarina
    Divacka, Petra
    Rehorova, Jitka
    Svojanovsky, Jan
    Hubacek, Jaroslav A.
    Lanska, Vera
    Kankova, Katerina
    [J]. GENE, 2024, 927
  • [23] Perspectives on T2DM from Clinicians and from People With T2DM in China: The EXPLORE Global Survey
    Yu, Xuefeng
    Wens, Johan
    Felton, Anne M.
    Islas, Ayeza Bonilla
    Schwarz, Peter E. H.
    Cobble, Michael E.
    [J]. DIABETES, 2013, 62 : A214 - A214
  • [24] Insulin Secretion and Sensitivity Pattern Is Different in patients With T2DM Only or Patients With T2DM and NAFLD
    Pan, Xiaoyu
    Liu, Qing
    Song, Kexiu
    Chai, Shangyu
    Li, Fei
    Huang, Yueye
    Bhavna, Bhavna
    Jhummon, Navina Priya
    Qu, Shen
    [J]. DIABETES, 2013, 62 : A492 - A492
  • [25] DIABETES Clinical inertia-a barrier to effective management of T2DM
    Lovshin, Julie A.
    Zinman, Bernard
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2013, 9 (11) : 635 - 636
  • [26] Survey to Specify SGLT2 Inhibitor Choice in T2DM Management
    Ghosal, Samit
    Joshi, Radhika M.
    Iyer, Rahul N.
    Adsule, Samir M.
    [J]. CLINICAL DIABETOLOGY, 2022, 11 (05): : 326 - 332
  • [27] Understanding Diabetes Self-Management: Thai Buddhists With T2DM
    Wattanakul, Boontuan
    Quinn, Laurie
    Ruggiero, Laurie
    Finnegan, Lorna
    Zerwic, Julie
    Ferrans, Carol
    Patel, Minu
    [J]. DIABETES, 2012, 61 : A205 - A205
  • [28] Intensive glycemic management leads to higher mortality in T2DM patients
    Kaufman, Michele B.
    [J]. FORMULARY, 2011, 46 (04) : 149 - 149
  • [29] Defining genetic risk of T2DM
    Claire Greenhill
    [J]. Nature Reviews Endocrinology, 2019, 15 : 438 - 438
  • [30] Mechanisms of hyperhomocysteinemia in T2DM with nephropathy
    Tessari, P
    Coracina, A
    Kiwanuka, E
    Vedovato, M
    Vettore, M
    Valerio, A
    Garibotto, G
    [J]. DIABETOLOGIA, 2005, 48 : A376 - A377
12345